Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma

KURTMAN C., Celebioǧlu B., Göǧüs O., Andrieu M.

International Urology and Nephrology, vol.32, no.2, pp.275-278, 2000 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 2
  • Publication Date: 2000
  • Doi Number: 10.1023/a:1007174213087
  • Journal Name: International Urology and Nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.275-278
  • Keywords: Prostatic carcinoma, Radiotherapy
  • Ankara University Affiliated: Yes

Abstract

The current study was undertaken to evaluate the Prostate Specific Antigen (PSA) relapse free survival and the prognostic factors in a total of 38 patients with stages of T2a-b, N0, M0 prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT). Mean 69.63 Gy was given with 3D-CRT, the mean follow up time was 13.89 months, and the mean prebiopsied PSA level was 25.12 ng/ml. The 2-year PSA relapse free survival was 47.37% for the entire group. The 2-year PSA relapse free survival rates were 100% and 44.74% for the patients with Gleason score ≤ 7 and greater than 7 (p ≤ 0.05). Patients with prebiopsied PSA level ≤ 10 ng/ml and the stages of T2a or T2b did not show any significant differences (p ≥ 0.05). Although the few case number and short term follow up, in this study 3D-CRT was a new effective technique to prostate cancer for our institutes and the Gleason score was important predictor of PSA relapse free survival.